VivoSeq
Neurology

Amyotrophic Lateral Sclerosis

188

Pipeline Programs↗

56

Active Trials↗

97

Companies Involved↗

Amyotrophic Lateral Sclerosis is a highly competitive landscape with 188 programs across 97 companies. The most active players are Ractigen Therapeutics., Denali Therapeutics Inc., RJK Biopharma Ltd. 14 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

52/100

Mech. Concentration

4/100

Completion Rate

77/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Ractigen Therapeutics.

1 program

Phase 1D

Denali Therapeutics Inc.

1 program

Phase 1R

RJK Biopharma Ltd

1 program

Phase 1C

Celosia Therapeutics Pty Ltd

1 program

Phase 1V

Verge Genomics

1 program

Phase 1Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical8

Ltx-002

Leal Therapeutics, Inc

Dronabinol

Alnylam Pharmaceuticals

HB-Admscs

Hope Biosciences Research Foundation

Trcn-1023

Trace Neuroscience, Inc.

Amivita

Wujin People's Hospital

Phase 140

Tenofovir Alafenamide

Gilead

Triheptanoin

Ultragenyx

Capsaicin

Averitas Pharma, Inc.

Tofacitinib

Prism Pharmaceuticals

Rabeprazole

Akero Therapeutics

Phase 2106

Basiliximab

Novartis

Riluzole

Azurity Pharmaceuticals

Anakinra

Swedish Orphan Biovitrum

Thalidomide

Bristol-Myers Squibb

Celecoxib

Philadelphia Eye Associates

Phase 320

Levosimendan

Orion Corporation, Orion Pharma

Dextromethorphan

Pfizer

Ravulizumab

AstraZeneca

Lithium Carbonate

Solvay Pharmaceuticals

Masitinib

AB Science

Approved14

Istradefylline

Kyowa Kirin Co., Ltd.

Ceftriaxone

Conrado Roberto Hoffmann Filho

Lacosamide

UCB

Tofersen

Biogen

Pramipexole

Boehringer Ingelheim

Analysis

Modality Breakdown

91%

Small molecule

180 of 198 classified programs — the dominant modality here.

9%ALL OTHERSCell therapy63%Protein / enzyme53%Monoclonal antibody42%Peptide1<1%RNA therapy1<1%Gene therapy1<1%

Small molecule leads; the ring shows all 198 classified programs, each share of the total. Modality classified for 98% of 221 pipeline programs.

Analysis

Trial Status

247

clinical trials

Completed131 · 53%
Terminated28 · 11%
Recruiting21 · 9%
Active, not recruiting19 · 8%
Unknown status16 · 6%
Not yet recruiting15 · 6%
Other17 · 7%

Clinical Trials

Trial Activity

247 trials

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT07193953·6 enrolled
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Recruiting·CCorcept Therapeutics·Phase 2·NCT05407324·279 enrolled
Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
Recruiting·SShanghai East Hospital·N/A·NCT06765564·3 enrolled
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
Recruiting·SStichting TRICALS Foundation·Phase 3·NCT06008249·171 enrolled
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
Recruiting·AAmylyx Pharmaceuticals Inc.·Phase 1·NCT06665165·48 enrolled
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis
Recruiting·PPRG Science & Technology Co., Ltd.·Phase 1·NCT07221240·48 enrolled
Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis
Recruiting·JJohns Hopkins University·Phase 1·NCT06656702·24 enrolled
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
Recruiting·XXellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.·Phase 1·NCT07118319·12 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
Recruiting·RRactigen Therapeutics.·Phase 1·NCT06556394·32 enrolled
Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)
Recruiting·—·Phase 1/2·NCT07414212·90 enrolled
A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
Recruiting·Biogen logoBiogen·Phase 4·NCT07223723·12 enrolled
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Recruiting·TTalengen Institute of Life Sciences, Shenzhen, P.R. China.·Phase 1/2·NCT06726577·60 enrolled
Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis
Recruiting·CCelosia Therapeutics Pty Ltd·Phase 1·NCT07401121·15 enrolled
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis
Recruiting·PPrilenia·Phase 3·NCT07322003·500 enrolled
Analysis of Human ALS Tissues and Registry of ALS Patients
Recruiting·UUniversity of Illinois at Chicago·N/A·NCT05067179·40 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)